New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
17:46 EDTANTHAnthera Pharmaceuticals reports Q2 EPS (34c), consensus (49c)
As of June 30, the company's cash, cash equivalents and restricted cash was $22.8M, compared to $35.9M at December 31, 2013.
News For ANTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 16, 2015
19:01 EDTANTHOn The Fly: After Hours Movers
UP AFTER EARNINGS: Bob Evans (BOBE), up 4%. ALSO HIGHER: Anthera Pharmaceuticals (ANTH), up 2.4% after meeting enrollment targets of Phase 3 clinical trial evaluating blisibimod. DOWN AFTER EARNINGS: DavidsTea (DTEA), down 10.8%... La-Z-Boy (LZB), down 3.9%... Adobe (ADBE), down 1.2%. ALSO LOWER: Azure Midstream Partners (AZUR), down 8.5% after announcing that it will offer 3.5M common units... Arena Pharmaceuticals (ARNA), down 2.3% after announcing CFO departure.
17:04 EDTANTHAnthera meets enrollment targets of Phase 3 clinical trial evaluating blisibimod
Anthera Pharmaceuticals announced that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is expected in the second half of 2016. Results from CHABLIS-SC1, and eventually CHABLIS-SC2, are anticipated to support marketing approval for blisibimod as a treatment for active SLE that is not controlled by current best practice standard-of-care, including corticosteroids.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use